Zobrazeno 1 - 10
of 39
pro vyhledávání: '"G. Boulle"'
Autor:
E. Mesny, J. Jacob, F. Culot, V. Calugaru, C. Jenny, B. Fonti, R. Bourdais, F. Courtault-Deslandes, G. Boulle, N. Meillan, J.-M. Simon, P. Maingon, L. Feuvret
Publikováno v:
Cancer/Radiothérapie. 26:678-683
Management of inter- and intra-fraction movements of target volumes and organs at risk (OARs) during radiotherapy is essential. While there is little OAR or target volume movement, the movements and orientation of the eyes can be significant during r
Autor:
Véronique Duchatelle, Diane Damotte, Y. Velut, R. Herbst, Ludovic Fournel, G. Boulle, Scott A. Hammond, M. Wislez, Isabelle Cremer, Laure Gibault, Philippe Giraud, Hélène Blons, Marco Alifano, Audrey Mansuet-Lupo, A. Boni, Jean Trédaniel
Publikováno v:
European Journal of Cancer
European Journal of Cancer, Elsevier, 2020, 135, pp.221-229. ⟨10.1016/j.ejca.2020.04.040⟩
European Journal of Cancer, 2020, 135, pp.221-229. ⟨10.1016/j.ejca.2020.04.040⟩
European Journal of Cancer, Elsevier, 2020, 135, pp.221-229. ⟨10.1016/j.ejca.2020.04.040⟩
European Journal of Cancer, 2020, 135, pp.221-229. ⟨10.1016/j.ejca.2020.04.040⟩
Background Radiotherapy is a standard of care for locally advanced stage III N2 non–small-cell lung carcinoma (NSCLC) combined with surgery/chemotherapy. Radiotherapy is hypothesised to induce tumour immunogenic cell death, to release neoantigen re
Autor:
François Goldwasser, Diane Damotte, G. Boulle, M. Wislez, Karen Leroy, Y. Velut, Marco Alifano, Isabelle Cremer, Jérôme Biton, Audrey Lupo
Publikováno v:
Revue de Pneumologie Clinique. 74:339-350
Immune checkpoint inhibitors (ICI), targeting the PD1/PD-L1 axis has shown their efficacy in lung cancer but only in a restricted population of patients, thus it is mandatory to identify biomarkers predicting the clinical benefit. In this article we
Autor:
Diane Damotte, Marco Alifano, G. Boulle, P. Giraud, A. Boni, Y. Velut, Audrey Lupo, J. Trédaniel
Publikováno v:
Cancer/Radiothérapie. 22:688-693
Recent therapeutic advances in non-small cell lung cancer allow a better understanding of the interactions between the tumour and its direct immune environment. The identification of new immune biomarkers integrating both cell subpopulations and thei
Autor:
M. Kissel, V. Martin, Florent Guérin, Hélène Martelli, C. Haie-Meder, Cyrus Chargari, T. Kumar, Stéphanie Bolle, E. Romano, G. Boulle, M. Andraud, R. Simon, Eric Deutsch
Publikováno v:
Radiotherapy and Oncology. 152:S1096-S1097
Autor:
E. Ullmann, A. Lombard, Nikos Paragios, N. Milhade, C. Robert, F. Nguyen, E. Romano, Pierre Blanchard, W. Zrafi, Vincent Grégoire, S. Bakkar, G. Boulle, A. Allajbej, Claire Petit, Eric Deutsch
Publikováno v:
Radiotherapy and Oncology. 152:S379-S380
Autor:
Nikos Paragios, Vincent Grégoire, Eric Deutsch, S. Bakkar, A. Munoz, E. Ullman, G. Boulle, G. Beldjoudi, T.V.F. Nguyen, N. Milhade, Claire Petit, A. Lombard, A. Allajbej, Pierre Blanchard, C. Robert
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 108:e780-e781
Autor:
S. Achkar, M. Andraud, E. Romano, C. Haie-Meder, M. Kissel, M.H. Ta, A. Duhamel, Cyrus Chargari, G. Boulle, B. Celestin, L. Bordenave, T. Kumar, V. Billard, R. Bourdais, A. Pounou
Publikováno v:
Radiotherapy and Oncology. 158:S142
Publikováno v:
Revue des Maladies Respiratoires Actualités. 7:361-366
Resume La radiotherapie en conditions stereotaxiques (ou SBRT : Stereotactic Body Radiation Therapy ) est un changement fondamental par rapport a la radiotherapie classique fractionnee et represente une nouvelle indication therapeutique. Elle est mai
Autor:
A, Lupo, M, Alifano, M, Wislez, G, Boulle, Y, Velut, J, Biton, I, Cremer, F, Goldwasser, K, Leroy, D, Damotte
Publikováno v:
Revue de pneumologie clinique. 74(5)
Immune checkpoint inhibitors (ICI), targeting the PD1/PD-L1 axis has shown their efficacy in lung cancer but only in a restricted population of patients, thus it is mandatory to identify biomarkers predicting the clinical benefit. In this article we